NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Immunization To Prevent Acute COPD Exacerbations

TerminatedN/A

Sponsor: Pfizer

Conditions: Pneumococcal Infections, COPD

Countries: Spain

Prospective multicenter observational study, to evaluate the impact of routine clinical practice vaccination with PCV13 on the reduction of the risk of moderate/severe COPD exacerbations

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

1. Patient ≥18 years diagnosed with COPD (any stage, the subgroups for the analysis would be based on COPD severity grade)
2. Ability to understand and complete the required QoL questionnaires
3. At least 2 years of clinical history available that includes records of previous moderate/severe exacerbations, influenza and pneumococcal vaccination history comorbidities and previous treatments.
4. Spirometry data (maximum 6 months old, or if not available at enrollment, to be performed as per normal clinical practice at visit 1 +/- one month)

Exclusion criteria:

1. Impossibility to perform prospective follow up
2. Present any immunocompromising condition
3. Present any other respiratory diseases as co-morbidity (subjects with overlap syndromes COPD-asthma will be excluded. Mixed phenotype defined as: symptoms of increased variability of airflow and incompletely reversible airflow obstruction)

Locations (11)

Palma, Balearic Islands, Spain
Terrassa, Barcelona, Spain
Ponferrada, LEÓN, Spain
Alcorcón, Madrid, Spain
Barcelona, Spain
Barcelona, Spain
Burgos, Spain
Madrid, Spain
Madrid, Spain
Madrid, Spain
Salamanca, Spain